The ethics of CYP2D6 testing for patients considering tamoxifen.
The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.
Hartman
Anne-Renee
AR
Menlo Park, CA 94025, USA. AnneRenee@gmail.com
Helft
Paul
P
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001675:Bioethics; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D005260:Female; D005820:Genetic Testing / Q000941:ethics*; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000941:ethics* / Q000379:methods*; D011110:Polymorphism, Genetic; D017698:Postmenopause; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6